Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY™ (Romosozumab) In Postmenopausal Women With Osteoporosis Read more about Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY™ (Romosozumab) In Postmenopausal Women With Osteoporosis
Repatha® (Evolocumab) Reduced Cardiovascular Events In Patients With Baseline LDL-C Levels Below Current Targets Read more about Repatha® (Evolocumab) Reduced Cardiovascular Events In Patients With Baseline LDL-C Levels Below Current Targets
Amgen Announces Voting Results of Annual Meeting of Stockholders Read more about Amgen Announces Voting Results of Annual Meeting of Stockholders
Amgen Submits Biologics License Application To The FDA For Erenumab Read more about Amgen Submits Biologics License Application To The FDA For Erenumab
Amgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio Read more about Amgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio
Amgen To Present At The Bank Of America Merrill Lynch 2017 Health Care Conference Read more about Amgen To Present At The Bank Of America Merrill Lynch 2017 Health Care Conference
Amgen And Harvard Pilgrim Agree To First Cardiovascular Outcomes-Based Refund Contract For Repatha® (Evolocumab) Read more about Amgen And Harvard Pilgrim Agree To First Cardiovascular Outcomes-Based Refund Contract For Repatha® (Evolocumab)
Amgen To Participate In The 2017 World Medical Innovation Forum™ Focused On Cardiovascular Disease Read more about Amgen To Participate In The 2017 World Medical Innovation Forum™ Focused On Cardiovascular Disease
Amgen Reports First Quarter 2017 Financial Results Read more about Amgen Reports First Quarter 2017 Financial Results
Amgen Announces Expanded Commercial Collaboration With Novartis For Erenumab In Migraine Read more about Amgen Announces Expanded Commercial Collaboration With Novartis For Erenumab In Migraine
